Skip to main content

Treatment Clinical Trials for Myelodysplastic Syndrome

Review the myelodysplastic syndrome treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 217

T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Luspatercept and Darbepoetin Alfa to Reduce Blood Transfusions in Non-mutated SF3B1 Lower-Risk Myelodysplastic Syndromes, DarbeLus Trial
Status: Active
Location: Yale University, New Haven, Connecticut
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Induction and Consolidation with Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Luspatercept for Treating Anemia in Patients with Myelodysplastic Syndromes or Myeloproliferative Neoplasms
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Canakinumab for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Statins for Preventing Progression of Disease in Patients with Clonal Cytopenia of Undetermined Significance or Lower-risk Myelodysplastic Syndrome
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Comparing Cyclophosphamide, Sirolimus, Ruxolitinib to Cyclophosphamide, Sirolimus, Mycophenolate Mofetil after Allogeneic Stem Cell Transplantation for the Prevention of Graft versus Host Disease in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older with Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Olutasidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, or Chronic Myelomonocytic Leukemia after Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Alpha/Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia or Telomere Biology Disorder
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Olutasidenib for the Treatment of Patients with IDH1-Mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Optimized Cord Blood Transplant with Intermediate Intensity Conditioning Regimen for the Treatment of Relapsed High-Risk Hematologic Cancers after First Donor Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CPX-351 (VYXEOS) for the Treatment of Secondary Myeloid Neoplasms in Patients Under 22 Years Old
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Decitabine with Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Azacitidine and Enasidenib in Treating Patients with IDH2-Mutant Myelodysplastic Syndrome
Status: Active
Location: 4 locations
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland